Application of MMP-14 inhibitor in preparation of medicines for treating blood vessel injury

A kind of MMP-14, 1. The technology of MMP-14, applied in the application field in medicine

Inactive Publication Date: 2018-11-20
SHIHEZI UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, no compound C 12 h 15 Cl 2 A report on the therapeutic effect of NO on vascular remodeling caused by intimal hyperplasia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of MMP-14 inhibitor in preparation of medicines for treating blood vessel injury
  • Application of MMP-14 inhibitor in preparation of medicines for treating blood vessel injury
  • Application of MMP-14 inhibitor in preparation of medicines for treating blood vessel injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1 (Application of MMP-14 inhibitors at various time points after carotid artery balloon injury in rats)

[0021] MMP-14 inhibitors were applied at different time points after carotid artery balloon injury in rats, and HE slices of the target blood vessels showed that the neointima in the injured group had obvious hyperplasia on the 7th day after operation, continued to proliferate on the 14th day, and reached the peak on the 28th day. In the MMP14 inhibitor group, there was no obvious neointimal hyperplasia at 7 days after operation, a little neointimal hyperplasia was seen at 14 days, and it reached the thickest at 28 days. The dose of MMP14 inhibitor with the most obvious inhibitory effect was 0.2 mg / monkey. Neointimal thickness / media thickness (I / M ratio) was used as the standard for evaluating the degree of neointimal hyperplasia. The results showed that in the MMP14 inhibitor group, the degree of neointimal hyperplasia at each time point was smaller than tha...

Embodiment 2

[0024] Embodiment 2 (MMP14 inhibitor cell experiment)

[0025] After adding MMP-14 inhibitors to vascular smooth muscle cells (VSMCs) and bone marrow mesenchymal stem cells (BMSCs) in vitro, Western blot was used to detect vascular smooth muscle cells (VSMCs) ) and bone marrow mesenchymal stem cells (bone mesenchymal stem cells, BMSCs) in the expression of MMP14; the results showed that the expression of MMP14 decreased.

[0026] The present invention detects the expression of MMP-14 at different time points after vascular injury in different groups by applying MMP-14 inhibitors at various time points after carotid artery balloon injury in rats, and the expression of MMP-14 in vascular smooth muscle cells (Vascular smooth muscle cells). Muscle cells, VSMCs) and bone marrow mesenchymal stem cells (bone mesenchymal stem cells, BMSCs) were applied with MMP-14 inhibitors, and their possible role in the formation of neointima was studied, and it was first proposed that MMP-14 inhib...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of an MMP-14 inhibitor in preparation of medicines for treating blood vessel injury, and relates to the technical field of biological pharmacy. According to the application of an MMP-14 inhibitor in preparation of medicines for treating blood vessel injury disclosed by the invention, the MMP-14 inhibitor is NSC 405020, the molecular formula of the MMP-14 inhibitor is C12H15Cl2NO, and the MMP-14 inhibitor is used for restraining newborn endomembrane proliferation after blood vessel injury. The invention further discloses a medicine for treating vascular diseases relevant to endangium proliferation. The medicine comprises the MMP-14 inhibitor. After carotid artery balloon injury of a rat, the MMP-14 inhibitor is applied at each time point, the expression situation of the MMP-14 at different time points after the blood vessel injury in different groups is detected, the effects that the MMP-14 inhibitor possibly exerts in the forming course of newborn endomembranes are researched, and the theory that the MMP-14 inhibitor can be used for treating diseases relevant to the blood vessel injury is provided for the first time.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to the application of an MMP-14 inhibitor in the preparation of medicines for treating vascular injury. Background technique [0002] With the development of the economy and the improvement of people's living standards, the morbidity and mortality of coronary heart disease are increasing year by year all over the world. In recent years, percutaneous coronary intervention (PCI) has been widely used clinically. Through balloon dilatation, stent placement, and arterial bypass surgery, although vascular reconstruction can be achieved, the blocked artery can be effectively dredged and the blood flow can be improved. for. However, different degrees of mechanical damage during the operation can cause the formation of neointima. According to statistics, 10%-20% of patients will experience vascular restenosis or re-occlusion within a period of time after surgery, resulting in coronary artery di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00A61K31/166A61P9/00
CPCA61K45/00A61K31/166A61P9/00
Inventor 庞丽娟郝颖王成燕
Owner SHIHEZI UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap